The goal of this clinical study is to learn more about the safety and tolerability ofobeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19).The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety andtolerability of ODV in pediatric participants with COVID-19.
Pediatric participants will be enrolled as follows:
- Cohort 1: ≥ 6 years to < 18 years and weight ≥ 40 kg
- Cohort 2: ≥ 6 years to < 18 years and weight ≥ 20 kg to < 40 kg
- Cohort 3: ≥ 2 years to < 18 years and weight ≥ 12 kg to < 20 kg
- Cohort 4: ≥ 28 days to < 18 years and weight ≥ 3 kg to < 12 kg
  -  Cohort 5: ≥ 14 days to < 28 days of age, gestational age (GA) ≥ 37 weeks and weight
     ≥ 2.5 kg
- Cohort 6: 0 days to < 14 days of age, GA ≥ 37 weeks and birth weight ≥ 2.5 kg
- Cohort 7: 0 days to < 56 days of age, GA < 37 weeks and birth weight ≥ 1.5 kg
Drug: Obeldesivir
Tablet administered orally with or without food
Other Name: GS-5245
Key Inclusion Criteria:
  -  Individual or legal guardian willing and able to provide written informed consent
     prior to performing study procedures. Individuals will provide assent, if possible,
     in accordance with local requirements and investigator's discretion.
  -  Aged < 18 years who meet one of the following weight criteria and gestational age
     (GA) criteria where applicable:
- Cohort 1: ≥ 6 years to < 18 years and weight ≥ 40 kg
- Cohort 2: ≥ 6 years to < 18 years and weight ≥ 20 kg to < 40 kg
- Cohort 3: ≥ 2 years to < 18 years and weight ≥ 12 kg to < 20 kg
- Cohort 4: ≥ 28 days to < 18 years and weight ≥ 3 kg to < 12 kg
- Cohort 5: ≥ 14 days to < 28 days of age, GA ≥ 37 weeks and weight ≥ 2.5 kg
- Cohort 6: 0 days to < 14 days of age, GA ≥ 37 weeks and birth weight ≥ 2.5 kg
- Cohort 7: 0 days to < 56 days of age, GA < 37 weeks and birth weight ≥ 1.5 kg
  -  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by
     polymerase chain reaction (PCR) or an alternative molecular diagnostic assay ≤ 5
     days before screening.
  -  Initial onset of coronavirus disease 2019 (COVID-19) signs/symptoms ≤ 5 days before
     screening with ≥ 1 sign/symptom such as fever, cough, fatigue, shortness of breath,
     sore throat, headache, myalgia/arthralgia present at screening.
  -  Presence of ≥ 1 characteristic or underlying medical condition associated with an
     increased risk of developing severe illness due to COVID-19 per protocol.
Key Exclusion Criteria:
  -  Anticipated access to and use of authorized or approved COVID-19 therapies during
     the current COVID-19 illness < 5 days after screening (therapies including but not
     limited to nirmatrelvir/ritonavir, molnupiravir, intravenous remdesivir (RDV),
     monoclonal antibodies).
  -  Vaccination for SARS-CoV-2 or self-reported history of SARS-CoV-2 infection < 4
     months prior to screening.
  -  Received any approved, authorized, or investigational direct acting antiviral drug
     against SARS-CoV-2 for the treatment of COVID-19 < 28 days or < 5 half-lives,
     whichever is longer, before enrollment.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trinity Clinical Research, LLC
Centreville	4054566, Alabama	4829764, United States
Advanced Research Center, Inc.
Anaheim	5323810, California	5332921, United States
Stanford University Medical Center
Palo Alto	5380748, California	5332921, United States
UF Health- Shands Hospital
Gainesville	4156404, Florida	4155751, United States
Encore Medical Research LLC
Hollywood	4158928, Florida	4155751, United States
Accel Research Sites Network - Nona Pediatric Center
Orlando	4167147, Florida	4155751, United States
Avanza Medical Research Center
Pensacola	4168228, Florida	4155751, United States
Santos Research Center
Tampa	4174757, Florida	4155751, United States
Pas Research
Tampa	4174757, Florida	4155751, United States
Velocity Clinical Research, Norfolk
Norfolk	5073965, Nebraska	5073708, United States
Velocity Clinical Research, Omaha
Omaha	5074472, Nebraska	5073708, United States
Pas Research
Las Vegas	5506956, Nevada	5509151, United States
Velocity Clinical Research -Albuquerque
Albuquerque	5454711, New Mexico	5481136, United States
Child Health Care Associates
East Syracuse	5116079, New York	5128638, United States
Velocity Clinical Research, Charleston
Charleston	4574324, South Carolina	4597040, United States
PanAmerican Clinical Research, LLC
Brownsville	4676740, Texas	4736286, United States
Texas Children's Hospital
Houston	4699066, Texas	4736286, United States
The University of Texas Medical School at Houston
Houston	4699066, Texas	4736286, United States
Gilead Study Director, Study Director
 Gilead Sciences